Therefore, simultaneous targeting of PD-L1 and HLA-G could amplify the efficacy of pemetrexed in vitro [201], having implications for designing rational combination treatments for clinical trials in NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.